At Pierre Fabre Pharmaceuticals Inc., our mission is to deliver breakthrough therapies to US patient populations with high unmet needs

In February 2024, Adriana Herrera joined Pierre Fabre to establish Pierre Fabre Pharmaceuticals, the company's new US pharmaceutical subsidiary. As Chief Executive Officer, Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy, and rare diseases, with an immediate focus on the commercialization of a groundbreaking allogeneic cell therapy for patients battling Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a rare and often fatal condition.

Adriana's professional experience has served to increase her passion and deep commitment to improving the lives of patients with significant unmet medical needs. Her leadership style, with a blend of decisiveness and executional excellence, underscores a strong belief in fostering talent and inclusive team cultures to achieve breakthrough outcomes.

Most recently, Adriana served as US General Manager at Kite Pharma, where she successfully commercialized the autologous CAR T-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for US Oncology, and high-impact leadership roles at Novartis Oncology, including Vice President and Global Diseases Lead for Lung and Genitourinary Cancers. Adriana commenced her career at Bristol Myers Squibb.

Adriana holds an MBA/MPH from Columbia Business School and Columbia Mailman School of Public Health. Away from work, she enjoys traveling with her husband and two daughters, reading, and walking her beloved dogs.

In her role as General Counsel, Compliance Officer & Corporate Secretary, Aisha leads the legal and compliance functions for Pierre Fabre Pharmaceuticals. She is responsible for all legal, regulatory, corporate security, privacy, business resilience, risk management, and litigation matters, and serves as the primary legal advisor for Executive Management and the Board of Directors. Aisha also supports the Dermo-Cosmetics legal entity Pierre Fabre USA. 

Aisha brings over 20 years of legal experience across multiple industries, with a strong business focus on providing strategic guidance to executive leadership teams and boards of directors. Her background includes providing guidance on complex transactions, pharmaceutical and regulatory law, corporate structure and governance, corporate commercial litigation, intellectual property, anti-trust compliance, and business development & licensing.

Aisha joined Pierre Fabre Pharmaceuticals after serving at Novartis in a variety of global and regional roles across the Oncology business unit. Most recently, Aisha was a Member of the Board of Directors, General Counsel & Chief Compliance Officer at Navigate BioPharma Services, Inc., a Novartis subsidiary in San Diego. Aisha previously served as a Senior Counsel within the US Solid Tumor and Hematology franchises, Head Legal for Global Marketing, Value & Access, the Cell and Gene division for Emerging Markets and Head Legal and Compliance for Middle East North Africa.  Aisha started her career in private practice before transitioning to Group General Counsel for a Swiss structured trade finance and collateral management company before joining Novartis.

Aisha holds an LLM (Master of Law) from University College, London and a BA LLB in Law from SOAS University of London, and qualified as a Barrister in the UK. She is licensed to practice as an Attorney in the State of New York. Outside of work, Aisha enjoys painting, swimming, traveling, and engaging in sports activities with her boys and their dog.

In her role as Vice President and Head of Medical Affairs, Lara Cavalli oversees medical affairs, scientific communications, and observational and interventional research in the US.

She brings 15 years of broad and deep healthcare and clinical experience developed during her tenures both in academia and in the pharmaceutical industry. Prior to joining Pierre Fabre Pharmaceuticals, Lara held roles of increasing responsibility at Bristol Myers Squibb. Most recently, she was Head of US Medical Affairs for their Cell Therapy franchise, contributing significantly to bringing to market several drugs to treat hematologic malignancies.

A professional with extensive experience in commercialization and clinical development through filing, approval, and launches in hematology and cell therapy, Cavalli is driven by her deep commitment to improving patient lives.

Lara holds a PharmD degree from Universià degli Studi di Parma, Italy, and completed a residency program in Medical Pharmacology at Università degli Studi di Milano, Italy.

Olivier Delannoy leads the growth and development of Hemangeol, a pivotal treatment within Pierre Fabre Pharmaceuticals' US portfolio. Aligning with the company's strategic focus on breakthrough therapies for targeted populations in oncology and rare diseases, Hemangeol is the only FDA-approved treatment indicated for infantile hemangioma.

Olivier has a proven record of driving operational excellence and strategic growth with over 25 years' experience in the Pharma/Biotech industry. His expertise includes leading successful therapeutic franchises all the way from inception to commercialization, designing and executing innovative market access and distribution strategies, and overseeing financial and business development deals.

Prior to joining Pierre Fabre Pharmaceuticals, Olivier served as Chief Operating Officer at Ovletude Life Sciences, a biotech company specializing in the development and commercialization of IVF treatments. Prior to that, he led commercial operations and sales management at Fidia Pharmaceuticals and Ferring Pharmaceuticals. He began his career in strategic consulting for the life sciences industry with AEC Partners in France.

Olivier holds a BBA in Finance from ISG Institut Supérieur de Gestion and an Executive MBA in Finance from HEC Paris.

As Head of Technical Operations, Adam Fenimore leads the US operations function, supporting the commercialization of Pierre Fabre Pharmaceuticals' first allogeneic cell therapy candidate and global supply chain. His extensive experience in managing the clinical manufacturing and distribution of highly complex products will be invaluable as future therapies in the rare disease arena move into development.

A technical business leader with over 25 years of industry experience, Adam has a proven track record of success in operational leadership roles within the pharmaceutical and biotech industries. His experience in building out robust commercial manufacturing operations will be critical as Pierre Fabre Pharmaceuticals establishes its US presence.

Prior to joining Pierre Fabre Pharmaceuticals, Adam served as Head of External Manufacturing at AlloVir. His professional experience also includes roles of increasing responsibility at Alkermes Pharmaceuticals and Serologicals Corporation.

Adam holds a Masters in Chemistry from the Illinois Institute of Technology, a Masters in Pharmaceutical Science from the University of Cincinnati, and an MBA in Management/Marketing from Xavier University. Outside of work, Adam adeptly manages the complex logistics of transporting his children to various seasonal youth sporting events while allocating any remaining time to watching English Premier League.

As Chief Financial Officer (CFO), Ilya is responsible for enabling Pierre Fabre Pharmaceuticals to maintain a strong financial position to deliver on its mission of improving the lives of patients with cancer and rare disease and supporting future innovation.

Ilya brings more than 15 years of global drug development, biotech, pharmaceutical business, and healthcare experience across a broad spectrum of finance roles in both public and private companies. He has an extensive record of success in challenging business environments, enabling companies to boost profits through effective financial planning and analysis, research and drug development resource allocation, and system and business integration.

Prior to joining the Pierre Fabre Pharmaceuticals executive team, Ilya was CFO, Senior Vice President, and Treasurer of BioCheck, Inc. Before that, he served senior finance leadership roles at City of Hope and at Novartis, where he served as Head of Finance in the Cell and Gene therapy unit. He began his career at Mars Inc., where he held positions of increasing responsibility in finance.

Ilya holds a BA in Finance from Valdosta State University and a BA in Accounting from Syktyvkar State University, and received his CMA certification from the Institute of Management Accountants.

As Business Operations Lead, Arthur Ginies oversees the operational functions of the organization, with a particular focus on leading the launch management for Pierre Fabre's first US allogeneic T-cell immunotherapy candidate. In addition, he is responsible for implementing cross-functional business strategies and structuring the US organization for long-term success, in alignment with Pierre Fabre's mission to discover new ways to care for patients with high unmet needs by delivering breakthrough therapies in oncology and rare diseases.

With over a decade of experience in life science consulting and the pharmaceutical industry, Arthur has a proven record in elaborating and executing business strategies, developing roadmaps designed to drive efficiency, innovation, and growth. He brings invaluable expertise from his consulting background in conducting business assessments to ensure seamless collaboration between functions at both local and corporate headquarters levels.

Most recently, Arthur served as Chief of Staff to the Pierre Fabre Group CEO. He originally joined Pierre Fabre Group in 2021 as an M&A Manager in Corporate Business Development. His 8-year tenure at EY included progressively responsible positions in Strategy & Transactions.

Arthur holds an MS in Management from ESSEC Business School, majoring in Corporate Finance. He is passionate about sports and plays competitive tennis and soccer. Having relocated to New York City, he enjoys walking around the lively streets of Manhattan and planning his travels.

As Head of the US Commercial organization, Seung Hyung-Moon spearheads the development and execution of commercial strategies to help unlock the potential of cell therapy and rare disease treatments for patients with high unmet medical need. He also serves as the US lead for Business Development in support of Pierre Fabre's efforts to build a robust and sustainable pipeline in the US.

With a rich biopharma background in leading and building innovative private or public biotech companies, Moon possesses a comprehensive understanding of commercial, medical, clinical, and business development functions. His professional experience includes developing and commercializing biologics and cell therapies for rare diseases in areas including hematology/oncology, neurology, nephrology, and hepatology.

Before joining Pierre Fabre Pharmaceuticals, he was Senior Vice President and US General Manager at AlloVir. Prior to that, he held leadership commercial positions at Alexion Pharmaceuticals and Handok Pharmaceuticals. He began his career as a general physician.

Josh leads the US Value and Access function, delivering the strategic vision to engage payors, educate providers, and ensure coverage and reimbursement of the Oncology portfolio of Pierre Fabre Pharmaceuticals.

He has extensive US and global market access experience across launch and inline products as well as molecules in early development. Josh brings a demonstrated ability to develop effective strategies in complex and competitive markets, drawing on his cross-functional experience in market access, marketing, and medical affairs.

Prior to joining the executive team, he led the US Market Access launch for a gene therapy product indicated for the treatment of severe hemophilia A. Before this role, Josh served in roles of increasing responsibility in Market Access at Shire. He began his career in medical affairs with Lilly and then GSK.

Josh received his PharmD from the University of the Sciences in Philadelphia.

In his role, Antonio leads all US pre- and post-submission activities, including regulatory, clinical and CMC strategy and maintenance, compliance, labeling, promotion, and safety. His passion for meeting the highest patient-safety and regulatory standards will be an asset to the company's strategy of delivering breakthrough therapies for cancers and rare diseases with high unmet need.

Antonio brings broad global regulatory affairs experience, with a track record of productive dialogue with regulators leading to product approvals in the US, Canada, Europe, Latin America, and Asia Pacific, as well as a demonstrated ability to manage complex regulatory processes and challenges.

Before joining the Pierre Fabre Pharmaceuticals executive committee, Antoni served as Head of Global Regulatory Compliance for Takeda. Prior to this, he served in senior-level regulatory affairs positions at Saol Therapeutics, Elekta, Teva Pharmaceuticals, Bayer, and Hospira.

Antonio earned a BSc in Pharmaceutical Chemistry from the Universidad Autónoma Metropolitana, an MSc in Pharmaceutical Sciences from King's College London, and an MBA from Universidad Iberoamericana.

Elizabeth Turcotte leads the development and execution of US patient strategy and serves as an enterprise-wide steward of the patient experience. She champions and oversees all strategic and operational aspects of patient engagement across advocacy, access, and education as well as culture and corporate communications.

Throughout her career, Elizabeth has been dedicated to enhancing the patient and customer experience. Her philosophy and approach are rooted in co-creating patient-centric services, programs, and educational resources alongside patients, caregivers, advocacy organizations, and healthcare providers. This ensures that patients' voices are heard and their needs effectively addressed.

Before joining Pierre Fabre Pharmaceuticals, Elizabeth served as Executive Director, Head of Patient Experience at Kite Pharma, where she successfully led the development and execution of an organization-wide patient experience strategy. Prior to that, she held leadership roles at Cisco and Bristol Myers Squibb, where she established the enterprise-level patient experience function and spearheaded the development of Universal Patient Language.

Elizabeth holds a BA in Economics from Binghampton University and an MBA from William & Mary School of Business. Outside of work, Elizabeth enjoys traveling and antiquing with her husband.